Clarivate (NYSE:CLVT) Given New $3.00 Price Target at Royal Bank Of Canada

Clarivate (NYSE:CLVT) had its price objective cut by Royal Bank Of Canada from $5.00 to $3.00 in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has a sector perform rating on the stock.

Several other analysts also recently issued reports on CLVT. The Goldman Sachs Group downgraded Clarivate from a “buy” rating to a “neutral” rating and cut their price target for the stock from $4.20 to $3.60 in a report on Thursday, January 8th. Wall Street Zen raised shares of Clarivate from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Morgan Stanley reiterated an “underweight” rating and issued a $3.00 price objective (down from $5.00) on shares of Clarivate in a research report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Clarivate in a research note on Monday, December 29th. Four analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Clarivate presently has a consensus rating of “Reduce” and a consensus price target of $3.30.

Clarivate Price Performance

CLVT opened at $2.30 on Wednesday. The company has a quick ratio of 0.87, a current ratio of 0.87 and a debt-to-equity ratio of 0.90. The company’s 50-day moving average price is $2.77 and its 200 day moving average price is $3.46. Clarivate has a fifty-two week low of $1.66 and a fifty-two week high of $4.77. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -7.65 and a beta of 1.51.

Insider Transactions at Clarivate

In related news, insider Bar Veinstein sold 309,902 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $3.74, for a total value of $1,159,033.48. Following the completion of the transaction, the insider owned 848,811 shares in the company, valued at $3,174,553.14. This represents a 26.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 23.18% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. M&T Bank Corp acquired a new position in shares of Clarivate during the fourth quarter valued at approximately $34,000. Essex Financial Services Inc. bought a new position in Clarivate during the 3rd quarter valued at $41,000. Jump Financial LLC acquired a new position in shares of Clarivate during the 4th quarter valued at $41,000. North Dakota State Investment Board acquired a new position in shares of Clarivate during the 4th quarter valued at $42,000. Finally, Beese Fulmer Investment Management Inc. bought a new stake in shares of Clarivate in the 4th quarter worth $44,000. 85.72% of the stock is currently owned by institutional investors.

Clarivate News Roundup

Here are the key news stories impacting Clarivate this week:

• Positive Sentiment: Reported Q4 results that beat consensus and issued stronger FY‑2026 EPS guidance (0.70–0.80 vs. consensus ~0.62), supporting near‑term earnings visibility. The company cited improved cash generation and provided detailed slides in its release. Clarivate Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Management outlined a target of ~10% free cash flow growth for 2026 and described a strategic portfolio shift intended to accelerate cash flow — this could improve capital allocation and deleverage over time. Clarivate outlines 10% free cash flow growth target for 2026
• Neutral Sentiment: The company confirmed it is in active discussions to sell its Life Sciences & Healthcare business as part of a strategic review. A sale could reduce debt or fund buybacks but also creates near‑term execution and timing uncertainty. Clarivate Reports Fourth Quarter and Full Year 2025 Results
• Negative Sentiment: Short interest jumped sharply in February to ~61.2M shares (up ~21% month‑over‑month), representing roughly 12% of float and a short‑interest ratio near 6.4 days — increased shorting adds selling pressure and volatility risk.
• Negative Sentiment: Barclays lowered its price target to $2.40 and moved to an “underweight” stance, signaling weaker analyst sentiment and likely weighing on the stock. Barclays cuts Clarivate PT to $2.40
• Negative Sentiment: RBC trimmed its target to $3.00 (now “sector perform”), another downgrade that could limit buyer interest despite RBC still showing upside to current levels. RBC lowers Clarivate PT to $3.00

Clarivate Company Profile

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.